Lunit Exclusively Provides 'AI Solution' at the World's Largest Immuno-Oncology Conference

Lunit and SITC Launch Free AI Biomarker Solution Support Program for Members
Lunit SCOPE IO Offers Advanced Tumor Microenvironment Analysis to SITC Researchers
Applications Open Until April 30 for Oncology, Pathology, and Immunology Experts

Lunit and SITC announced on the 3rd that they will launch a research support program that temporarily provides the AI (artificial intelligence) biomarker solution 'Lunit SCOPE IO' free of charge to SITC members.

Lunit SCOPE IO is an AI solution trained on a vast amount of H&E slide image data. It precisely quantifies the distribution of tumor-infiltrating lymphocytes (TIL), a key indicator for predicting the response to immune checkpoint inhibitor therapy, and analyzes the tumor microenvironment (TME) to classify it into three immune phenotypes (IP): Inflamed, Immune-excluded, and Immune-desert.

This type of analysis is very complex, with many elements subject to the observer's subjective judgment. The need for AI-based analysis has been continuously raised. The Lunit SCOPE product line, including Lunit SCOPE IO, is regarded as an approach that overcomes the limitations of these conventional methods.

This program is open to physicians (MD) or researchers holding a PhD degree affiliated with academic or non-profit research institutions who have SITC membership. In particular, the principal investigator is required to have expertise in oncology, pathology, or immunology, and final selection will be made through a review based on the research proposal and the investigator’s resume. The application period is from the 1st of this month to April 30th.

To inform its members about this program, SITC has created a page introducing Lunit SCOPE IO on its official website and plans to introduce the program through the February and March issues of 'Immune Monitor,' the official email newsletter for SITC members and the immunology and oncology communities.

Seobum Seok, CEO of Lunit, said, "We are pleased that more global researchers can utilize Lunit’s AI technology through this collaborative program with SITC, a world-renowned authority in the field of immuno-oncology. We will continue to expand cooperation with leading research institutions worldwide to lead the paradigm shift in healthcare driven by AI technology."

Mary Dean, Secretary General of SITC, stated, "SITC has led advancements in the field of immuno-oncology for the past 40 years, striving to improve treatment outcomes for cancer patients. We hope this program will further advance the research of SITC members."

Meanwhile, since Lunit became the first domestic medical AI company to present research results at SITC in 2021, it has demonstrated innovative research achievements for four consecutive years, proving its technological capabilities and leadership in the global immuno-oncology treatment field.

This content was produced with the assistance of AI translation services.